Fas I -tutkimus annoksen kohottamiseksi ja annoksen laajentamiseksi subkutaanisen durvalumabin farmakokinetiikan ja turvallisuuden tutkimiseksi (IMFINZI-subQ)
Faasin I, monikestuksinen, annosvaikelu- ja annoslaajennustukimus ihonalaisen durvalumabin farmakokineetiikan ja turvallisuuden tutkimiseksi aikuisilla kiinteitä kasvaimia sairastavilla osallistujilla
The purpose of the study is to determine a subcutaneous (SC: under the skin) durvalumab + recombinant human hyaluronidase (rHu) dose that yields systemic drug exposure similar to intravenous (IV: into the veins) durvalumab administration and to evaluate the pharmacokinetics and safety of SC durvalumab + rHu injection in participants with different types of solid tumours (cancers).
Tutkimuksen yleiskatsaus
Tila
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
This is a Phase I, multicentre study that will consist of 2 parts -
- Part 1: Dose Escalation
- Part 2: Dose Expansion
Part 1 may include participants with solid tumours - non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC) or limited-stage small cell lung cancer (LS-SCLC). It will further consist of 2 planned dose levels of SC durvalumab - Dose level 1 (DL1) and Dose level 2 (DL2).
Part 2 will include participants with unresectable HCC. It will be initiated once a dose has been identified based on Part 1.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: AstraZeneca Clinical Study Information Center
- Puhelinnumero: 1-877-240-9479
- Sähköposti: information.center@astrazeneca.com
Opiskelupaikat
-
-
-
Fitzroy, Australia, 3065
- Peruutettu
- Research Site
-
St Albans, Australia, 3021
- Peruutettu
- Research Site
-
Woolloongabba, Australia, 4102
- Peruutettu
- Research Site
-
-
-
-
-
Seongnam-si, Etelä -Korea, 13620
- Rekrytointi
- Research Site
-
Seoul, Etelä -Korea, 06351
- Rekrytointi
- Research Site
-
Seoul, Etelä -Korea, 5505
- Rekrytointi
- Research Site
-
Seoul, Etelä -Korea, 03722
- Rekrytointi
- Research Site
-
-
-
-
-
Batumi, Georgia, 6010
- Rekrytointi
- Research Site
-
Tbilisi, Georgia, 0114
- Rekrytointi
- Research Site
-
Tbilisi, Georgia, 0112
- Rekrytointi
- Research Site
-
-
-
-
-
Brzozów, Puola, 36-200
- Rekrytointi
- Research Site
-
Koszalin, Puola, 75-581
- Rekrytointi
- Research Site
-
Lublin, Puola, 20-090
- Rekrytointi
- Research Site
-
Olsztyn, Puola, 10-357
- Rekrytointi
- Research Site
-
Przemyśl, Puola, 37-700
- Rekrytointi
- Research Site
-
-
-
-
-
Tainan, Taiwan, 73657
- Rekrytointi
- Research Site
-
Taipei, Taiwan, 112
- Peruutettu
- Research Site
-
Taipei, Taiwan, 110
- Rekrytointi
- Research Site
-
Taoyuan, Taiwan, 333
- Peruutettu
- Research Site
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy of ≥ 12 weeks at enrolment.
- Adequate organ and marrow function.
- Minimum body weight > 30 kg.
Part 1 only:
Locally Advanced Unresectable (Stage III) NSCLC Participants -
- Histological or cytological documented evidence of NSCLC (locally advanced, unresectable, Stage III).
- Must have received at least 2 cycles of platinum-based chemotherapy concurrent with definitive radiation therapy.
- Have not progressed following definitive concurrent chemoradiation.
LS-SCLC Participants -
- Histologically or cytologically documented LS-SCLC (Stage I-III).
- Received 4 cycles of chemotherapy concurrent with radiotherapy, which must be completed within 1 to 42 days prior to enrolment.
- Have not progressed following definitive concurrent chemoradiation.
Part 1 and 2:
Unresectable HCC Participants -
- Unresectable HCC based on histopathological confirmation.
- No prior systemic therapy for unresectable HCC.
- Must not be eligible for locoregional therapy for unresectable HCC.
- Child-Pugh Score class A.
- Measurable disease as defined by RECIST v1.1.
Exclusion Criteria:
- Active or prior documented autoimmune disease requiring systemic treatment.
- Uncontrolled infection (including human immunodeficiency virus [HIV], hepatitis B or C).
- Prior exposure to immune checkpoint inhibitors.
Part 1 only:
Locally Advanced Unresectable (Stage III) NSCLC Participants -
- Mixed SCLC and NSCLC histology.
- Active pneumonitis or interstitial lung disease requiring systemic therapy.
LS SCLC Participants -
- Mixed SCLC and NSCLC histology.
- Extensive-stage disease.
- History of Grade ≥ 2 pneumonitis.
Part 1 and 2:
Unresectable HCC Participants -
- Hepatic encephalopathy.
- Uncontrolled ascites.
- Active gastrointestinal (GI) bleeding.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Part 1: SC Durvalumab DL1
Participants will receive DL1 of SC durvalumab + rHu followed by IV durvalumab at predefined intervals. |
Durvalumab + rHu will be administered subcutaneously. Durvalumab will be administered intravenously.
Muut nimet:
Tremelimumab will be administered to participants with unresectable HCC as an IV infusion. |
|
Kokeellinen: Part 1: SC Durvalumab DL2
Participants will receive DL2 of SC durvalumab + rHu followed by IV durvalumab at predefined intervals. |
Durvalumab + rHu will be administered subcutaneously. Durvalumab will be administered intravenously.
Muut nimet:
Tremelimumab will be administered to participants with unresectable HCC as an IV infusion. |
|
Kokeellinen: Part 2: Expansion Cohort, SC Durvalumab Dose Level X
Participants will receive dose level X (determined from data analysis in Part 1) of SC durvalumab + rHu followed by IV durvalumab at predefined intervals. |
Durvalumab + rHu will be administered subcutaneously. Durvalumab will be administered intravenously.
Muut nimet:
Tremelimumab will be administered to participants with unresectable HCC as an IV infusion. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Area under the concentration-time curve
Aikaikkuna: From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the AUC of SC durvalumab. |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
|
Observed lowest concentration before the next dose is administered (Ctrough)
Aikaikkuna: From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the Ctrough of SC durvalumab |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Area under the concentration-time curve from time 0 to last quantifiable concentration (AUClast)
Aikaikkuna: From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the AUClast of SC durvalumab. |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
|
Maximum observed concentration (Cmax)
Aikaikkuna: From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the Cmax of SC durvalumab. |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
|
Time to reach maximum concentration following drug administration (tmax)
Aikaikkuna: From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the tmax of SC durvalumab. |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
|
Terminal elimination half-life (t1/2λz)
Aikaikkuna: From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the t1/2λz of SC durvalumab. |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
|
Total body clearance/apparent total body clearance (CL[/F])
Aikaikkuna: From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the CL(/F) of SC durvalumab. |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
|
Apparent volume of distribution based on the terminal phase volume (Vz[/F])
Aikaikkuna: From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the VZ(/F) of SC durvalumab. |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
|
Average drug concentration over a dosing interval (Cavg)
Aikaikkuna: From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the Cavg of SC durvalumab. |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
|
Serum concentration of durvalumab
Aikaikkuna: From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
To characterise the serum concentration of SC durvalumab at specified timepoints. |
From first dose of study intervention (Day 1), at predefined intervals throughout the administration of durvalumab (approximately 17 months).
|
|
Number of participants with adverse events (AEs)
Aikaikkuna: Up to Survival Follow-up (approximately 17 months)
|
To assess the safety and tolerability of SC durvalumab. |
Up to Survival Follow-up (approximately 17 months)
|
|
Number of participants with dose-limiting toxicities (DLTs)
Aikaikkuna: Up to Survival Follow-up (approximately 17 months)
|
To assess the safety and tolerability of SC durvalumab. |
Up to Survival Follow-up (approximately 17 months)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
- Monoklonaalinen vasta-aine
- Farmakokinetiikka
- Ihonalainen
- Ohjelmoitu solukuolemaproteiini 1
- Ohjelmoitu solukuoleman ligandi 1 (PD-L1)
- Syövän vastainen terapia
- Pienisoluiseen keuhkosyöpään verrattuna suurisoluinen keuhkosyöpä (vaihe III, leikkauskelvoton)
- Pienisoluinen keuhkosyöpä (Rajoittunut vaihe)
- Hepatosellulaarinen karsinooma (leikattavissa olematon)
- Ihmisen hyaluronidaasi
Muita asiaankuuluvia MeSH-ehtoja
- Neoplasmat sivustoittain
- Neoplasmat
- Hengityselinten sairaudet
- Neoplasmat histologisen tyypin mukaan
- Ruoansulatuskanavan kasvaimet
- Ruoansulatuskanavan sairaudet
- Keuhkosairaudet
- Maksasairaudet
- Kasvaimet, rauhas- ja epiteelikasvaimet
- Adenokarsinooma
- Maksan kasvaimet
- Hengitysteiden kasvaimet
- Rintakehän kasvaimet
- Keuhkojen kasvaimet
- Karsinooma
- Syöpä, bronkogeeninen
- Keuhkoputkien kasvaimet
- Karsinooma, hepatosellulaarinen
- Karsinooma, ei-pienisoluinen keuhko
- Pienisoluinen keuhkosyöpä
- durvalumabi
- vammi
Muut tutkimustunnusnumerot
- D907HC00001
- 2025-521639-34-00 (Muu tunniste: EU CT number)
- 2025 (Yhdysvaltain NIH-apuraha/sopimus)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD-jaon aikakehys
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD-jaon käyttöoikeuskriteerit
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .